BioHeart
Bioheart CEO makes 1st public appearance since emergency cardiac surgery
Neuro Kinetics appoints new CFO | Personnel Moves
Neuro Kinetics appointed Michael Saporito as its new CFO.
Saporito joins the Pittsburgh-based medical device company after years with LifeVest, which he helped turn around before the company was bought out by Zoll Medical.
Bioheart launches clinical trial for stem cell vision loss therapy
Biolase quashes rumors of CEO departure | Personnel Moves
Bioheart to ask FDA for “compassionate use” permit for cardiac stem cell therapies
Sunrise, Fla.-based regenerative therapies maker Bioheart Inc. is preparing to ask the FDA to allow "compassionate use" of its cell therapies outside of clinical trial settings.
Bioheart hopes to gain expanded access for its MyoCell and LipiCell treatments in certain heart failure patients who have limited alternative options for treatment, according to a press release.
EndoStim takes funding round to $11M | Wall Street Beat
EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.
Johnson & Johnson hits 52-week high on boosted earnings forecast | Wall Street Beat
Shares of Johnson & Johnson (NYSE:JNJ) surged to a 52-week high today after the healthcare conglomerate boosted its 2012 earnings forecast after reporting a solid, Street-beating quarter (and despite a nearly 18% bottom-line slide).